Search

Your search keyword '"Shen, Yongxiang"' showing total 21 results
Start Over Author "Shen, Yongxiang"
21 results on '"Shen, Yongxiang"'

4. Stability bound analysis of singularly perturbed systems with time-delay

Author

Sun Fengqi, Yang Chunyu, Zhang Qingling, and Shen Yongxiang

Subjects
singularly perturbed systems, stability bound, linear matrix inequality, Lyapunov-Krasovskii functional, Chemical engineering, TP155-156, Chemical industries, HD9650-9663
Abstract

This paper considers the stability bound problem of singularly perturbed systems with time-delay. Some stability criteria are derived by constructing appropriate Lyapunov-Krasovskii functionals. The proposed criteria are less conservative than the existing ones. Two numerical examples are given to illustrate the advantages and effectiveness of the proposed methods.

Published
2013
Full Text
View/download PDF

8. High Child-Pugh and CRUB65 scores predict mortality of decompensated cirrhosis patients with COVID-19: A 23-center, retrospective study

Author

Xiao, Yong, primary, Wu, Dongwen, additional, Shi, Xiao, additional, Liu, Shuzhong, additional, Hu, Xudong, additional, Zhou, Chenliang, additional, Tian, Xia, additional, Liu, Huimin, additional, Long, Hui, additional, Li, Zhihong, additional, Wang, Ji, additional, Tan, Tao, additional, Xu, Ying, additional, Chen, Bitao, additional, Liu, Ting, additional, Zhang, Heng, additional, Zheng, Shihua, additional, Hu, Shunlin, additional, Song, Jun, additional, Tang, Jie, additional, Song, Jichun, additional, Cheng, Zhengwei, additional, Xu, Weitian, additional, Shen, Yongxiang, additional, Yu, Wenhu, additional, Xu, Yong, additional, Li, Jiao, additional, Zhou, Jing, additional, Wang, Fen, additional, and Chen, Mingkai, additional

Published
2021
Full Text
View/download PDF

15. MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls

Author

He, Lilin and Shen, Yongxiang

Subjects
meta-analysis, breast cancer, ovarian cancer, MTHFR, OncoTargets and Therapy, Original Research, C677T, polymorphism
Abstract

Lilin He, Yongxiang Shen Department of Oncology, The First People’s Hospital of Tianmen City, Tianmen, Hubei Province, People’s Republic of China Objective: Previous studies have found that many gene variations can be detected in both breast cancer and ovarian cancer, which is beneficial for the elaboration of the molecular origin of breast and ovarian cancer. Furthermore, many studies have explored the association of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism with the risk of breast cancer and/or ovarian cancer; however, the results remained inconclusive. Therefore, this study conducted a systematic review and meta-analysis to evaluate the association between MTHFR C677T polymorphism and the risk of breast and ovarian cancer. Materials and methods: A total of 50 studies with 19,260 cases and 26,364 controls including 39 studies for breast cancer and 8 studies for ovarian cancer were identified on searching through PubMed, Embase, Web of Science, China National Knowledge Infrastructure, WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP). Allele model, dominant model, recessive model, homozygous model, and co-dominant model were applied to evaluate the association of MTHFR C677T polymorphism with breast cancer and/or ovarian cancer risk. Moreover, the odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association between MTHFR C677T polymorphism and breast and ovarian cancer risk. Results: A significantly increased breast cancer risk was observed in the overall analysis (for C vs T, OR =1.19, CI: 1.12–1.28, P

Published
2017

16. MTHFR C677T polymorphism and breast, ovarian cancer risk: a meta-analysis of 19,260 patients and 26,364 controls

Author

He,Lilin, Shen,Yongxiang, He,Lilin, and Shen,Yongxiang

Abstract

Lilin He, Yongxiang Shen Department of Oncology, The First People’s Hospital of Tianmen City, Tianmen, Hubei Province, People’s Republic of China Objective: Previous studies have found that many gene variations can be detected in both breast cancer and ovarian cancer, which is beneficial for the elaboration of the molecular origin of breast and ovarian cancer. Furthermore, many studies have explored the association of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism with the risk of breast cancer and/or ovarian cancer; however, the results remained inconclusive. Therefore, this study conducted a systematic review and meta-analysis to evaluate the association between MTHFR C677T polymorphism and the risk of breast and ovarian cancer. Materials and methods: A total of 50 studies with 19,260 cases and 26,364 controls including 39 studies for breast cancer and 8 studies for ovarian cancer were identified on searching through PubMed, Embase, Web of Science, China National Knowledge Infrastructure, WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP). Allele model, dominant model, recessive model, homozygous model, and co-dominant model were applied to evaluate the association of MTHFR C677T polymorphism with breast cancer and/or ovarian cancer risk. Moreover, the odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association between MTHFR C677T polymorphism and breast and ovarian cancer risk. Results: A significantly increased breast cancer risk was observed in the overall analysis (for C vs T, OR =1.19, CI: 1.12–1.28, P<0.05; for CC vs TT, OR =1.20, CI: 1.10–1.23, P<0.05; for (CT+CC) vs TT, OR =1.19, CI: 1.11–1.27, P<0.05; for CC vs (CT+TT), OR =1.19, CI: 1.79–1.95, P<0.05), while no significantly increased ovarian cancer risk was detected. In the subgroup analysis based on ethnicity, a significant

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results